180 Life Sciences Corp. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)

3 Months Ended

Mar. 31, 2023

	Warrants
	Public			Private
	SPAC			SPAC			PIPE			Other			Total
Balance as of January 1, 2023	$	31,625		$	1,256		$	42,100		$	400		$	75,381
Change in fair value of derivative liabilities		(21,390	)		(1,005	)		(30,600	)		(328	)		(53,323	)
Balance as of March 31, 2023	$	10,235		$	251		$	11,500		$	72		$	22,058

Schedule of option pricing models

	March 31, 2023
Risk-free interest rate		3.71% - 4.40	%
Expected term in years		1.34 – 2.90
Expected volatility		103.5% - 106.0	%
Expected dividends		0	%
Market Price	$	1.80

	December 31, 2022
Risk-free interest rate		2.30% - 4.50	%
Expected term in years		1.59 – 3.90
Expected volatility		76.0% - 105.0	%
Expected dividends		0	%
Market Price	$	3.39

- Definition

Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.

+ References + Details